RT Journal Article
SR Electronic
T1 Eradication of Medullary Multiple Myeloma by CD4<sup>+</sup> Cytotoxic Human T Lymphocytes Directed at a Single Minor Histocompatibility Antigen
JF Clinical Cancer Research
JO Clin Cancer Res
FD American Association for Cancer Research
SP 5481
OP 5488
DO 10.1158/1078-0432.CCR-10-1340
VO 16
IS 22
A1 Spaapen, Robbert M.
A1 Groen, Richard W.J.
A1 van den Oudenalder, Kelly
A1 Guichelaar, Teun
A1 van Elk, Maureen
A1 Aarts-Riemens, Tineke
A1 Bloem, Andries C.
A1 Storm, Gert
A1 Martens, Anton C.
A1 Lokhorst, Henk M.
A1 Mutis, Tuna
YR 2010
UL http://clincancerres.aacrjournals.org/content/16/22/5481.abstract
AB Purpose: The essential role of CD4+ T cells as helpers of anticancer immunity is indisputable. Little is known, however, about their capacity to serve as effector cells in cancer treatment. Therefore, we explored the efficacy of immunotherapy with sole CD4+ cytotoxic human T cells directed at a hematopoietic-restricted minor histocompatibility antigen (mHag).Experimental Design: In macrophage-depleted Rag2−/−γc−/− mice, which were also devoid of T, B, and natural killer cells, mHag-specific native T cells or tetanus toxoid (TT)-specific T cells transduced with the mHag-specific T-cell receptor (TCR) were injected to treat full-blown mHag+ human multiple myeloma tumors.Results: mHag-specific antitumor responses were achieved after injection of native or mHag-TCR-transduced T cells. Although the therapy completely eradicated the primary tumors in the bone marrow, it failed to control extramedullary relapses, even after repeated T-cell injections. Detailed analyses ruled out mHag or MHC downregulation as mechanisms of extramedullary tumor escape. Impaired T-cell survival in vivo or defective homing to the tumor site were also ruled out as mechanisms behind extramedullary relapses, because injections of TT-loaded antigen presenting cells could facilitate homing of long-term surviving T cells to s.c. tumor sites. Moreover, intratumoral treatment of extramedullary tumors with 3AB11 was also ineffective.Conclusions: Taken together, these results for the first time show the feasibility of immunotherapy of primary bone marrow tumors with sole CD4+ human T cells directed to a tumor-associated mHag. Extramedullary relapses, probably due to microenvironment-dependent inhibitory mechanisms, remain a challenging issue towards effective cellular immunotherapy of hematologic malignancies. Clin Cancer Res; 16(22); 5481–8. ©2010 AACR.